Table 3.
Time on treatment rates at 6, 9 and 12 months.
| 6-Month on- Treatment Rates |
9-Month on- Treatment Rates |
12-Month on- Treatment Rates |
|
|---|---|---|---|
| Age | |||
| <70 years | 70.5 (63.0–78.8) | 59.9 (51.9–69.1) | 52.2 (44.1–61.8) |
| ≥70 years | 58.3 (47.2–71.9) | 55.0 (44.0–68.9) | 41.1 (30.0–56.2) |
| Gender | |||
| Female | 73.8 (64.7–84.1) | 63.3 (53.4–74.9) | 53.5 (43.3–66.0) |
| Male | 61.3 (52.9–71.1) | 54.8 (46.2–64.9) | 45.3 (36.7–55.9) |
| BRAF status | |||
| BRAF negative | 64.0 (55.0–74.5) | 59.6 (50.5–70.5) | 49.9 (40.5–61.4) |
| BRAF positive | 64.9 (54.9–76.7) | 49.2 (38.9–62.3) | 41.8 (31.7–55.0) |
| AJCC stage (8th edition) | |||
| Stage IIIA | 85.7 (72.0–100) | 73.8 (56.3–96.8) | 61.5 (42.5–89.2) |
| Stage IIIB | 66.2 (54.3–80.6) | 62.2 (50.1–77.1) | 53.5 (41.2–69.5) |
| Stage IIIC | 63.1 (54.8–72.6) | 53.0 (44.6–63.1) | 43.1 (34.7–53.6) |
| Stage IIID * | 66.7 (37.9–100) | 66.7 (37.9–100) | 66.7 (37.9–100) |
Time on treatment (TOT) at 6, 9 and 12 months. AJCC: American Joint Committee on Cancer; BRAF: BRAF mutation status. * Estimates are uncertain due to the small number of patients (n = 7).